Spectranetics Announces Resolution of Federal Investigation

Spectranetics Corporation (“Company”) (Nasdaq: SPNC) today reported the settlement of matters related to the federal investigation initiated by the Food & Drug Administration and U.S. Immigration and Customs Enforcement, which was previously announced in a press release dated September 4, 2008.

The resolution includes a non-prosecution agreement and a civil settlement agreement with the United States Department of Justice, as well as a Corporate Integrity Agreement with the Office of the Inspector General for the United States Department of Health and Human Services. Significant terms of the agreements, subject to certain conditions outlined therein, include an agreement not to prosecute the Company, a $4.9 million payment in consideration of a release from certain civil or administrative monetary claims resulting from certain alleged conduct associated with the federal investigation, and a separate agreement that specifies certain corporate integrity obligations.

SenoRx Found Not Liable for Patent Infringement

SenoRx, Inc. (Nasdaq:SENO) today announced that a jury delivered a verdict in favor of SenoRx in a lawsuit brought by Hologic, Inc., Cytyc Corp., and Hologic L.P. (Hologic) in the U.S. District Court for the Northern District of California. Hologic had alleged that SenoRx infringed claims of Hologic's 6,413,204 and 6,482,142 patents. SenoRx claimed that both patents were invalid, and that the '204 patent was not infringed.

The jury found that SenoRx was not liable for infringement of the '204 patent and that both patents were invalid. Lloyd Malchow, SenoRx Chairman and Chief Executive Officer, said, "We are pleased with the jury's verdict. We have been steadfast from the beginning and confident in our position. We look forward to focusing all of management's time on continuing to develop innovative new products to assist and improve the medical community's ability to diagnose and more effectively treat breast cancer."

TSO3 Receives Health Canada clearance for STERIZONE(R) 125L+ Sterilizer

TSO3 Inc. ("TSO3") (TSX: TOS.TO), an innovator of low temperature sterilization technology using ozone for medical devices in healthcare settings, today announced that Health Canada has approved the STERIZONE(R) 125L+ Sterilizer for sale in Canada.

The STERIZONE(R) 125L+ Sterilizer offers three new cycles in a single sterilizer and meets healthcare demands for speed and compatibility that previously required two or more sterilization systems. The device will be available through 3M Canada's distribution in 2010.

"This market clearance in Canada is perfectly timed with our recently announced distribution agreement with 3M, a global leader in infection prevention," stated R.M. (Ric) Rumble, CEO, TSO3. "The partnership with 3M adds credibility and channel strength, and we are working with 3M Canada to capitalize on the opportunity."

OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months

Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted the 12-month results of the OrBIT Trial of its Urgent® PC Neuromodulation System that will be published in the January 2010 print edition of THE JOURNAL OF UROLOGY®. The Urgent PC System is a proprietary, minimally invasive, percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder (OAB).

The long-term phase of the OrBIT Trial reported on 25 patients who had significant symptom improvement in the initial 12-week phase of the OrBIT Trial and continued PTNS therapy at increasing time intervals between treatments over a 12-month period.